|
|||||
|
|
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study |
|
| Authors: | Kåre I. Birkeland MD Johan Bodegard MD Amitava Banerjee MD Dae Jung Kim MD Anna Norhammar MD Jan W. Eriksson MD Marcus Thuresson PhD Suguru Okami PhD Kyoung Hwa Ha PhD Nils Kossack MSc Jil Billy Mamza PhD Ruiqi Zhang PhD Toshitaka Yajima MD Issei Komuro MD Takashi Kadowaki MD |
| Affiliation: | 1. Oslo University Hospital and University of Oslo, Oslo, Norway;2. AstraZeneca, Oslo, Norway;3. Institute of Health Informatics, University College London, London, UK Department of Cardiology, University College London Hospitals, London, UK;4. Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Republic of Korea;5. Cardiology Unit, Department of Medicine, Karolinska Institute, Solna, Sweden Capio S:t Görans Hospital, Stockholm, Sweden;6. Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden;7. Statisticon AB, Uppsala, Sweden;8. AstraZeneca, Osaka, Japan;9. Wissenschaftliches Institut für Gesundheitsökonomie und Gesundheitssystemforschung, Leipzig, Germany;10. AstraZeneca, Luton, UK;11. Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;12. Tranomon Hospital, Tokyo, Japan |
| Abstract: | |
| Keywords: | dapagliflozin diabetic nephropathy DPP-IV inhibitor heart failure observational study SGLT2 inhibitor |